J&J-Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care

Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1 Data show a nearly 50 percent reduction in disease progression in BRCA-altered mHSPC1 BEERSE, BELGIUM, June 03, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson announced today first results from the Phase 3, randomised, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patien ...